Cheryl Madsen

Cheryl Madsen joins Viracta Therapeutics from Calithera Biosciences where she served as Vice President of Regulatory Affairs.  Previously, Cheryl was the Vice President of Regulatory Affairs at Peloton Therapeutics where she facilitated the successful acquisition of their HIF2-α inhibitor (belzutifan) by Merck.  Prior to that Cheryl served as Sr. Director at Medivation (acquired by Pfizer), where she played an instrumental role in the initial global regulatory filings, approval and launch of XTANDI® (enzalutamide) for the treatment of metastatic castration-resistant prostate cancer.  In addition to her regulatory responsibilities, she served as Project Team Leader for XTANDI from 2015-2016.  Prior to Medivation, she held positions of increasing responsibility at several successful small- to medium-size biotechnology companies.  Cheryl started her career at Genentech, and during her 13‑year tenure, was responsible for the original filing and approval of AVASTIN® (bevacizumab) for first-line metastatic colorectal cancer.  She played a critical role in the parallel filing and approval of the HERCEPTIN® (trastuzumab) BLA for metastatic breast cancer and the HercepTest™ PMA, an in vitro diagnostic for HER2 expression and patient selection.  Cheryl received her bachelors degree in Psychology from U.C. Santa Cruz and completed additional post-graduate work in Molecular Biology and Biochemistry at U.C. Berkeley.  She holds U.S. and Global Regulatory Affairs Certifications from the Regulatory Affairs Professional Society.